Pacira Pharmaceuticals Inc (PCRX) VP Sells $50,700.00 in Stock

Pacira Pharmaceuticals Inc (NASDAQ:PCRX) VP Lauren Bullaro Riker sold 1,000 shares of the company’s stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $50.70, for a total value of $50,700.00. Following the transaction, the vice president now directly owns 11,474 shares of the company’s stock, valued at $581,731.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Lauren Bullaro Riker also recently made the following trade(s):

  • On Wednesday, August 22nd, Lauren Bullaro Riker sold 1,667 shares of Pacira Pharmaceuticals stock. The stock was sold at an average price of $44.48, for a total value of $74,148.16.

Shares of PCRX traded up $0.25 during trading hours on Wednesday, hitting $48.95. 1,172,700 shares of the stock were exchanged, compared to its average volume of 858,668. The company has a debt-to-equity ratio of 0.98, a quick ratio of 7.79 and a current ratio of 8.58. Pacira Pharmaceuticals Inc has a 12-month low of $26.95 and a 12-month high of $52.60. The stock has a market capitalization of $2.07 billion, a price-to-earnings ratio of -84.31 and a beta of 1.99.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, August 2nd. The company reported $0.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.13) by $0.37. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The firm had revenue of $84.10 million during the quarter, compared to analysts’ expectations of $77.53 million. During the same period in the previous year, the business earned ($0.11) earnings per share. The firm’s revenue for the quarter was up 18.6% on a year-over-year basis. analysts predict that Pacira Pharmaceuticals Inc will post -0.21 earnings per share for the current year.

Several brokerages have recently weighed in on PCRX. Royal Bank of Canada set a $55.00 target price on Pacira Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, September 19th. Stifel Nicolaus began coverage on Pacira Pharmaceuticals in a research note on Thursday, September 13th. They set a “sell” rating and a $41.00 target price for the company. ValuEngine downgraded Pacira Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, September 11th. Canaccord Genuity set a $45.00 target price on Pacira Pharmaceuticals and gave the stock a “hold” rating in a research note on Tuesday, September 4th. Finally, TheStreet upgraded Pacira Pharmaceuticals from a “d+” rating to a “c” rating in a research report on Friday, August 10th. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and nine have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus price target of $47.11.

Institutional investors and hedge funds have recently modified their holdings of the stock. State of Wisconsin Investment Board grew its holdings in Pacira Pharmaceuticals by 3.0% in the 2nd quarter. State of Wisconsin Investment Board now owns 40,600 shares of the company’s stock valued at $1,301,000 after buying an additional 1,200 shares in the last quarter. Rhumbline Advisers grew its holdings in Pacira Pharmaceuticals by 3.5% in the 2nd quarter. Rhumbline Advisers now owns 39,897 shares of the company’s stock valued at $1,279,000 after buying an additional 1,335 shares in the last quarter. US Bancorp DE grew its holdings in Pacira Pharmaceuticals by 53.8% in the 1st quarter. US Bancorp DE now owns 4,292 shares of the company’s stock valued at $134,000 after buying an additional 1,501 shares in the last quarter. Fisher Asset Management LLC grew its holdings in Pacira Pharmaceuticals by 29.6% in the 1st quarter. Fisher Asset Management LLC now owns 6,848 shares of the company’s stock valued at $213,000 after buying an additional 1,566 shares in the last quarter. Finally, Summit Trail Advisors LLC grew its holdings in Pacira Pharmaceuticals by 12.9% in the 1st quarter. Summit Trail Advisors LLC now owns 15,103 shares of the company’s stock valued at $400,000 after buying an additional 1,728 shares in the last quarter.

About Pacira Pharmaceuticals

Pacira Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology.

Read More: How to calculate the intrinsic value of a stock

Insider Buying and Selling by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply